Publications @ the Saelens Group
- Schepens, B. et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med 6, 1436–1454 (2014).
- Schotsaert, M. et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunology 6, 276–287 (2013).
- Verhelst, J. et al. Interferon-Inducible Protein Mx1 Inhibits Influenza Virus by Interfering with Functional Viral Ribonucleoprotein Complex Assembly. Journal of Virology 86, 13445–13455 (2012).
- Schepens, B. et al. Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion. Journal of Infectious Diseases 204, 1692–1701 (2011).
- El Bakkouri, K. et al. Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection. Journal of Immunology 186, 1022–1031 (2011).
- A reassortant H9N2 influenza virus containing 2009 pandemic H1N1 internal-protein genes acquired enhanced pig-to-pig transmission after serial passages in swine.
- Effect of serial pig passages on the adaptation of an avian H9N2 influenza virus to swine.
- Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.
- Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
- Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.
- IgG3 Snitcher of RSV Infections in the Very Young.
- Hierarchical and redundant roles of activating FcγRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies.
- Chemical-controlled activation of antiviral Myxovirus Resistance 1.
- Production and Purification of Recombinant Filamentous Bacteriophages Displaying Immunogenic Heterologous Epitopes.
- Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.